Profile data is unavailable for this security.
About the company
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
- Revenue in GBP (TTM)2.63m
- Net income in GBP-35.77m
- Incorporated2018
- Employees80.00
- LocationRenalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
- Phone+44 292 071 0570
- Websitehttps://renalytix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abingdon Health PLC | 6.14m | -1.27m | 15.01m | 85.00 | -- | 4.37 | -- | 2.45 | -0.0104 | -0.0104 | 0.0484 | 0.0178 | 1.10 | 6.38 | 4.28 | 72,176.47 | -22.70 | -52.46 | -35.04 | -85.00 | 59.97 | 35.93 | -20.72 | -121.70 | 1.70 | -63.00 | 0.3181 | -- | 51.67 | 21.92 | 63.36 | -- | -15.69 | -- |
| Inspiration Healthcare Group PLC | 34.30m | -9.76m | 15.47m | 224.00 | -- | 0.5531 | -- | 0.4509 | -0.1421 | -0.1421 | 0.4985 | 0.3119 | 0.6557 | 1.54 | 4.11 | 153,120.50 | -18.66 | 1.04 | -22.64 | 1.28 | 44.88 | 47.61 | -28.46 | 1.16 | 1.15 | -1.75 | 0.3472 | -- | -8.74 | 19.43 | -2,318.38 | -- | 32.41 | -- |
| Belluscura PLC | 1.40m | -14.40m | 17.77m | 35.00 | -- | 1.17 | -- | 12.72 | -0.1003 | -0.1003 | 0.0095 | 0.0905 | 0.0742 | 0.3954 | 0.3956 | 39,911.57 | -76.44 | -49.84 | -84.73 | -54.78 | -33.28 | -66.07 | -1,030.73 | -1,277.34 | 2.09 | -10.15 | 0.00 | -- | -40.96 | 27.44 | -127.13 | -- | 41.32 | -- |
| Polarean Imaging PLC | 1.45m | -6.61m | 18.80m | 29.00 | -- | 1.54 | -- | 13.00 | -0.0249 | -0.0249 | 0.0054 | 0.0101 | 0.1075 | 0.5109 | 1.84 | 49,864.84 | -49.18 | -61.45 | -58.32 | -69.17 | 44.78 | 50.68 | -457.39 | -810.92 | 5.24 | -- | 0.0093 | -- | -13.75 | -18.24 | 14.53 | -- | 64.51 | -- |
| Ondine Biomedical Inc | 909.26k | -7.94m | 24.39m | 43.00 | -- | 2,298.54 | -- | 26.82 | -0.036 | -0.036 | 0.0041 | 0.00004 | 0.2859 | 0.5497 | 9.93 | -- | -249.74 | -- | -597.99 | -- | 60.04 | -- | -873.56 | -- | 0.4828 | -- | 0.9487 | -- | 88.56 | -- | 25.60 | -- | -- | -- |
| ANGLE plc | 2.02m | -18.03m | 26.62m | 150.00 | -- | 1.09 | -- | 13.15 | -0.0684 | -0.0684 | 0.0077 | 0.076 | 0.0553 | 0.3117 | 1.21 | 13,493.33 | -49.30 | -- | -55.77 | -- | 69.07 | -- | -890.91 | -- | 4.80 | -- | 0.1469 | -- | 109.99 | -- | 7.17 | -- | -- | -- |
| Renalytix PLC | 2.63m | -35.77m | 26.83m | 80.00 | -- | 0.5253 | -- | 10.19 | -0.4379 | -0.4379 | 0.032 | 0.1523 | 0.0646 | 2.88 | 4.06 | 32,921.05 | -87.73 | -58.25 | -120.00 | -67.03 | 20.60 | -- | -1,358.30 | -1,904.79 | 1.71 | -9.62 | 0.397 | -- | 14.58 | -- | 18.52 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Ruffer LLPas of 01 Nov 2024 | 28.50m | 17.18% |
| Unicorn Asset Management Ltd.as of 09 Oct 2024 | 18.96m | 11.42% |
| Harwood Capital LLPas of 09 Oct 2024 | 14.19m | 8.55% |
| Polar Capital LLPas of 20 Sep 2024 | 13.87m | 8.36% |
| Jefferson River Capital LLCas of 20 Sep 2024 | 8.53m | 5.14% |
| Pentwater Capital Management LPas of 01 Nov 2024 | 5.79m | 3.49% |
| Lombard Odier Asset Management (Europe) Ltd.as of 24 Apr 2024 | 4.00m | 2.41% |
| Heights Capital Management, Inc.as of 25 Jun 2024 | 2.01m | 1.21% |
| Gilder, Gagnon, Howe & Co. LLCas of 12 Mar 2024 | 1.52m | 0.92% |
| Susquehanna Investment Group LLCas of 26 Jun 2024 | 1.42m | 0.85% |
